文献速递肝病

去甲熊去氧胆酸改善原发性硬化性胆管炎的胆汁淤积

norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
PubMed 文献 · J Hepatol · 2017-05-18

这项随机对照试验纳入161例未合并UDCA治疗且碱性磷酸酶升高的原发性硬化性胆管炎患者,比较口服去甲熊去氧胆酸500、1000、1500mg/d与安慰剂的疗效。治疗12周后,去甲熊去氧胆酸使碱性磷酸酶相对基线分别变化-12.3%、-17.3%、-26.0%,安慰剂组为+1.2%,安全性良好,作者认为可开展III期试验。

要点

  • 去甲熊去氧胆酸500、1000、1500mg/d组碱性磷酸酶分别降低12.3%、17.3%、26.0%,安慰剂组升高1.2%。
  • 去甲熊去氧胆酸的安全性与安慰剂相当,瘙痒报告率与安慰剂组无差异。
  • 作者认为该结果支持在原发性硬化性胆管炎患者中开展去甲熊去氧胆酸的III期试验。

核心结论

  • 去甲熊去氧胆酸在所有治疗组中呈剂量依赖性显著降低碱性磷酸酶水平,安全性与安慰剂相当,作者认为该结果支持开展III期试验。

研究设计与样本

  • 随机对照试验,纳入来自12个欧洲国家的38个中心,共161例未合并UDCA治疗且血清碱性磷酸酶升高的原发性硬化性胆管炎患者。
  • 患者随机接受口服去甲熊去氧胆酸500mg/d、1000mg/d或1500mg/d或安慰剂治疗12周,随后随访4周。
  • 主要疗效终点为基线至治疗结束访视时碱性磷酸酶水平的平均相对变化。

主要发现

  • 去甲熊去氧胆酸500、1000、1500mg/d组碱性磷酸酶分别降低12.3%、17.3%、26.0%,与安慰剂比较p=0.029、p=0.003、p<0.0001;安慰剂组升高1.2%。
  • 次要终点如ALT、AST、γ-GT或达到碱性磷酸酶<1.5×ULN的患者比例也呈相似的剂量依赖性结果。
  • 严重不良事件在500mg/d组7例、1000mg/d组5例、1500mg/d组2例、安慰剂组3例。
  • 治疗组与安慰剂组之间报告的瘙痒无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIM: Primary sclerosing cholangitis (PSC) represents a devastating bile duct disease, currently lacking effective medical therapy. 24-norursodeoxycholic acid (norUDCA) is a side chain-shortened C23 homologue of UDCA and has shown potent anti-cholestatic, anti-inflammatory and anti-fibrotic properties in a preclinical PSC mouse model. A randomized controlled trial, including 38 centers from 12 European countries, evaluated the safety and efficacy of three doses of oral norUDCA (500mg/d, 1,000mg/d or 1,500mg/d) compared with placebo in patients with PSC. METHODS: One hundred sixty-one PSC patients without concomitant UDCA therapy and with elevated serum alkaline phosphatase (ALP) levels were randomized for a 12-week treatment followed by a 4-week follow-up. The primary efficacy endpoint was the mean relative change in ALP levels between baseline and end of treatment visit. RESULTS: norUDCA reduced ALP levels by -12.3%, -17.3%, and -26.0% in the 500, 1,000, and 1,500mg/d groups (p=0.029, p=0.003, and p<0.0001 when compared to placebo), respectively, while a +1.2% increase was observed in the placebo group. Similar dose-dependent results were found for secondary endpoints, such as ALT, AST, γ-GT, or the rate of patients achieving ALP levels <1.5× ULN. Serious adverse events occurred in seven patients in the 500mg/d, five patients in the 1,000mg/d, two patients in the 1500mg/d group, and three in the placebo group. There was no difference in reported pruritus between treatment and placebo groups. CONCLUSIONS: norUDCA significantly reduced ALP values dose-dependently in all treatment arms. The safety profile of norUDCA was excellent and comparable to placebo. Consequently, these results justify a phase III trial of norUDCA in PSC patients. Lay summary: Effective medical therapy for primary sclerosing cholangitis (PSC) is urgently needed. In this phase II clinical study in PSC patients, a side chain-shortened derivative of ursodeoxycholic acid, norursodeoxycholic acid (norUDCA), significantly reduced serum alkaline phosphatase levels in a dose-dependent manner during a 12-week treatment. Importantly, norUDCA showed a favorable safety profile, which was similar to placebo. The use of norUDCA in PSC patients is promising and will be further evaluated in a phase III clinical study. ClinicalTrials.gov number: NCT01755507.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Fickert P, Hirschfield GM, Denk G, et al. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol. 2017. PMID: 28529147. doi:10.1016/j.jhep.2017.05.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。